...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Great Discussion
10
Oct 16, 2017 12:10PM
9
Oct 16, 2017 01:45PM
4
Oct 16, 2017 02:01PM

Oct 16, 2017 02:42PM
5
Oct 16, 2017 03:04PM
2
Oct 16, 2017 05:51PM
3
Oct 16, 2017 10:35PM
2
Oct 18, 2017 06:19PM
2
Oct 18, 2017 06:22PM

I certainly would not want to see Zenith and RVX but back together again. Why?

  1. Don is the Chairman of both boards.
  2. The boards are essentailly almost all insiders with 4 members being the same for each companies.
  3. The boards do not have any "heavy hitters" on the business development side that could create the credibility, connections, financial perspectives,etc as independent outsiders.
  4. Don wields too much power over other board members.
  5. Don gas completely blown it with RVX. That has become obvious. A few years ago I was posting about how I felt Don should be building the awareness, understanding, credibility and interest for the RVX brand and rvx-208 among a broad base of potential investors and explaining the potential for this Canadian company in order to build brand equity. By failing to build brand equity Don left himself and RVX in the power of Hepa and Eastern and possibly others. He has hired a VP of IR that has achieved nothing on the brand visibility side. Also, if Don had built the brand he may have had a chance at a NASDAQ lisitng and this would have provided credibilty with USA investors.
  6. For Zenith Don, rather flippantly, twice stated he was going to do a resverse takeover of a distressed company that already has either a TSX and/or NASDAQ listing and then he walked away from that.
  7. Don has shown no indication that he will create liquidity for Zenith shareholders.
  8. The Zenith portfolio of compounds seems to be directed at different indications than RVX and in particular various cancers. I sense that cancers are a very different set of biochemical processes than RVX. With all of the billions of dollars spent researching various cancers and treatments progress is slow. When a cancer drug has some success the cancers seem to adjust to the drug and start growing again. It is my understanding that enzalutimde has this problem and zen3694 is designed to re-establish enzalutimide's effectiveness. I read some posts about the zen3694 trial update and it seems there are some positive results. I sense it is very early days for Zenith and development will take years and millions of $ to develop equity.

 If there is a blending of Hepa's share ppower across Zenith then we may not just be lsoing RVX but Zenith could be gone as well.

Oh well, just my rambling thoughts. Hope they spark counter points. Also, I hope zen3694 is a blockbuster! I'd love to eat crow.

GLTA

Toinv

 

2
Oct 19, 2017 12:43PM
1
Oct 19, 2017 01:06PM
Share
New Message
Please login to post a reply